Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells $33,592.14 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,586 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the sale, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. This trade represents a 5.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Barry Ticho also recently made the following trade(s):

• On Friday, December 6th, Barry Ticho sold 13,945 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10.
• On Monday, December 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.07, for a total value of $120,700.00.

Stoke Therapeutics Stock Down 2.1 %

NASDAQ:STOK traded down $0.28 on Wednesday, reaching $12.98. 283,002 shares of the company’s stock traded hands, compared to its average volume of 748,105. The stock has a 50-day simple moving average of $12.46 and a 200-day simple moving average of $13.68. The firm has a market cap of $687.55 million, a PE ratio of -6.15 and a beta of 0.95. Stoke Therapeutics, Inc. has a 12 month low of $4.09 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on STOK. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and a consensus target price of $20.83.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at $19,835,000. SG Americas Securities LLC lifted its stake in shares of Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after buying an additional 58,943 shares in the last quarter. RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Stoke Therapeutics by 54.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after buying an additional 36,240 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.